Australia

Australian Cancer Pioneer Richard Scolyer Dies at 59

Is brain cancer research hopelessly stagnant or has Richard Scolyer's immunotherapy breakthrough finally changed the game?

Published JUN 8

Australian Cancer Pioneer Richard Scolyer Dies at 59

Story

Above: Georgina Long (L) and Richard Scolyer in Canberra on Jan. 24, 2024. Image credit: Alex Ellinghausen/Sydney Morning Herald/Getty Images

The Facts

Australian cancer specialist Richard Scolyer died on Sunday, aged 59, after nearly three years battling glioblastoma, one of the most aggressive forms of brain cancer. Prime Minister Anthony Albanese confirmed Scolyer would receive a state funeral.
News.com.au
9News Australia
Scolyer became the first brain cancer patient in the world to receive a combination of immunotherapy drugs before surgery, an approach adapted from melanoma research he developed alongside colleague Professor Georgina Long. A personalized cancer vaccine was also administered as part of the experimental treatment.
The Sydney Morning Herald
BBC News
The Australian
Scolyer's brain tumor showed signs of recurrence in March 2025, as scans revealed it was growing rapidly on the left side of his brain following surgery that could not remove the entire mass. He had previously announced being 18 months cancer-free in November 2024.
ABC Australia
Australian Financial Review
The experimental treatment prompted a clinical trial in the United States, led by Australian oncologist Mustafa Khasraw at Duke University Cancer Institute. A further trial was also being prepared at the Peter MacCallum Cancer Centre in Melbourne.
ABC Australia
Daily Mail
The Australian
Scolyer and Long were jointly named the 2024 Australian of the Year for their pioneering melanoma research, which improved the five-year survival rate for patients with advanced melanoma from around 5% to 55%. In September 2025, the Australian government committed $5.9 million to establish the Richard Scolyer Chair in Brain Cancer Research at Chris O'Brien Lifehouse in Sydney.
9News Australia
Reuters
In a letter released after his death, Scolyer wrote that he had "dedicated my 35-year working life to patient care, cancer research and improving lives." He co-authored more than 900 peer-reviewed publications and lectured at more than 400 conferences during his career.
9News Australia
The Sydney Morning Herald
The Age on Youtube

Sources Split

LEFT

CENTER

RIGHT

ESTAB
CRIT

CENTER

PRO
ESTAB

The Spin

Narrative A

Brain cancer research has been stuck in neutral for two decades while other cancers have seen dramatic breakthroughs. The five-year survival rate for aggressive brain cancer remains below 5%, even as melanoma survival has surged past 50%. Coordinated, well-funded research teams are the only path forward — and the science Scolyer generated proves bold immunotherapy approaches deserve serious investment now.

Richard Scolyer on Instagram

guardian

Narrative B

Richard Scolyer didn't just face a terminal diagnosis — he turned it into a scientific breakthrough that will reshape brain cancer treatment for generations. His world-first immunotherapy regimen extended his life nearly two years beyond what standard treatment would have offered, and the clinical trial it sparked at Duke University means future patients will directly benefit. That's a legacy that transcends one life.